Breast Cancer Clinical Trials in Ann Arbor, Michigan
11 recruitingAnn Arbor, Michigan
Showing 1–11 of 11 trials
Recruiting
Phase 4
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
Breast CancerEsophageal CancerMetastatic Gastric Cancer
University of Michigan Rogel Cancer Center22 enrolled1 locationNCT05183126
Recruiting
Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
Breast CancerDepression
NRG Oncology402 enrolled277 locationsNCT06748222
Recruiting
Not Applicable
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast CancerCognitive Impairments
NRG Oncology386 enrolled680 locationsNCT05896189
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled12 locationsNCT07211178
Recruiting
Phase 1
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
Breast Cancer
University of Michigan Rogel Cancer Center30 enrolled3 locationsNCT05996107
Recruiting
Integrated Cancer Repository for Cancer Research
Breast CancerLiver CancerEsophageal Cancer+47 more
University of Nebraska999,999 enrolled45 locationsNCT02012699
Recruiting
Phase 2
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Breast Cancer
BicycleTx Limited66 enrolled39 locationsNCT06840483
Recruiting
Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Breast Cancer
Canadian Cancer Trials Group2,140 enrolled475 locationsNCT03488693
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Not Applicable
Adaptive Symptom Self-Management Immunotherapy Study
Breast CancerLung CancerColon Cancer+2 more
University of Arizona400 enrolled3 locationsNCT05715255